Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals

References

• Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. doi:10.1136/thoraxjnl-2011-201518
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. NEJM. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
   PubMed Web of Science ®Google Scholar
• Hillas G, Perlikos F, Tzanakis N. Acute exacerbation of COPD: is it the “stroke of the lungs”? Int J Chron Obstruct Pulmon Dis. 2016;11:1579–1586. doi:10.2147/COPD.S106160
   PubMed Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21(7):1152–1165. doi:10.1111/resp.12780
   PubMed Web of Science ®Google Scholar
• Kim JK, Lee SH, Lee BH, et al. Factors associated with exacerbation in mild- to-moderate COPD patients. Int J Chron Obstruct Pulmon Dis. 2016;11:1327–1333. doi:10.2147/COPD.S105583
   PubMed Web of Science ®Google Scholar
• Müllerová H, Shukla A, Hawkins A, Quint J. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ Open. 2014;4(12):e006171. doi:10.1136/bmjopen-2014-006171
   PubMed Web of Science ®Google Scholar
• Andreas S, Taube C. Inhaled therapy reduces COPD mortality. ERJ Open Res. 2020;6(4):00634–02020. doi:10.1183/23120541.00634-2020
   PubMedGoogle Scholar
• Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(8):619–626. doi:10.1016/s2213-2600(17)30207-2
   PubMed Web of Science ®Google Scholar
• Merinopoulou E, Raluy-Callado M, Ramagopalan S, MacLachlan S, Khalid JM. COPD exacerbations by disease severity in England. Int J Chron Obstruct Pulmon Dis. 2016;11:697–709. doi:10.2147/copd.s100250
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.847
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Voorham J, Dorinsky P, et al. The long-term burden of COPD exacerbations during maintenance therapy and lung function decline. Int J Chron Obstruct Pulmon Dis. 2020;15:1909–1918. doi:10.2147/copd.s253812
   PubMed Web of Science ®Google Scholar
• Hurst JR, Donaldson GC, Quint JK, Goldring JJP, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(5):369–374. doi:10.1164/rccm.200807-1067OC
   PubMed Web of Science ®Google Scholar
• Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis. 2013;8:551–559. doi:10.2147/copd.s51507
   PubMed Web of Science ®Google Scholar
• Milne RJ, Beasley R. Hospital admissions for chronic obstructive pulmonary disease in New Zealand. N Z Med J. 2015;128(1408):23–35.
   PubMed Web of Science ®Google Scholar
• Harries TH, Thornton H, Crichton S, Schofield P, Gilkes A, White PT. Hospital readmissions for COPD: a retrospective longitudinal study. NPJ Prim Care Respir Med. 2017;27(1):31. doi:10.1038/s41533-017-0028-8
   PubMed Web of Science ®Google Scholar
• Hurst J, Shanahan L, Imoedemhe E, et al.; National Asthma and Chronic Obstructive Pulmonary Disease Audit Programme (NACAP). Outcomes of patients included in the 2017/18 COPD clinical audit (patients with COPD exacerbations discharged from acute hospitals in England and Wales between September 2017 and September 2018). Audit report. London: Royal College of Physicians; 2020. Available from: https://www.nacap.org.uk/nacap/welcome.nsf/vwFiles/NACAP-COPD-SC-202007a/$File/NACAP_COPD_SC_Outcomes_2017-18_Report_290620.pdf?openelement. Accessed September 17, 2020.
   Google Scholar
• Soler-Cataluña JJ, Martínez-García MÁ, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Resp Med. 2009;103(5):692–699. doi:10.1016/j.rmed.2008.12.005
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. 2021 global strategy for prevention, diagnosis and management of COPD. Available from: https://goldcopd.org/2021-gold-reports/. Accessed December 18, 2020.
   Google Scholar
• Chen X, Wang N, Chen Y, Xiao T, Fu C, Xu B. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. Int J Chron Obstruct Pulmon Dis. 2016;11:2625–2632. doi:10.2147/COPD.S118523
   PubMed Web of Science ®Google Scholar
• Nishimura S, Zaher C. Cost impact of COPD in Japan: opportunities and challenges? Respirology. 2004;9(4):466–473. doi:10.1111/j.1440-1843.2004.00617.x
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.9709032
   PubMed Web of Science ®Google Scholar
• Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008;133(1):34–41. doi:10.1378/chest.07-1692
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Donaldson GC, Hurst JR, Seemungal TAR, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(12):1298–1303. doi:10.1164/rccm.200310-1443OC
   PubMed Web of Science ®Google Scholar
• Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(3):316–325. doi:10.1513/AnnalsATS.201309-305OC
   PubMedGoogle Scholar
• Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156–1165. doi:10.1183/09031936.00038814
   PubMed Web of Science ®Google Scholar
• Xu W, Collet JP, Shapiro S, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Resp J. 2010;35(5):1022–1030. doi:10.1183/09031936.00079409
   PubMed Web of Science ®Google Scholar
• Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177(4):396–401. doi:10.1164/rccm.200708-1290OC
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904. doi:10.2147/COPD.S62750
   PubMed Web of Science ®Google Scholar
• Albitar HAH, Iyer VN. Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the real world: current understanding, barriers, and solutions. Curr Opin Pulm Med. 2020;26(2):149–154. doi:10.1097/MCP.0000000000000655
   PubMed Web of Science ®Google Scholar
• Worth H, Buhl R, Criee CP, Kardos P, Mailander C, Vogelmeier C. The ‘real-life’ COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64–71. doi:10.1016/j.rmed.2015.12.010
   PubMed Web of Science ®Google Scholar
• Tabyshova A, Hurst JR, Soriano JB. Gaps in COPD guidelines of low- and middle-income countries: a systematic scoping review. Chest. 2021;159(2):575–584. doi:10.1016/j.chest.2020.09.260
   PubMed Web of Science ®Google Scholar
• Khunti K, Davies MJ. Clinical inertia-time to reappraise the terminology? Prim Care Diabetes. 2017;11(2):105–106. doi:10.1016/j.pcd.2017.01.007
   PubMed Web of Science ®Google Scholar
• Price DB, Yawn BP, Jones RCM. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin Proc. 2010;85(12):1122–1129. doi:10.4065/mcp.2010.0389
   PubMed Web of Science ®Google Scholar
• van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016;2016(8):Cd010744. doi:10.1002/14651858.CD010744.pub2
   PubMed Web of Science ®Google Scholar
• Maqsood U, Ho TN, Palmer K, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3(3):Cd012930. doi:10.1002/14651858.CD012930.pub2
   PubMedGoogle Scholar
• Ni H, Moe S, Soe Z, Myint KT, Viswanathan KN. Combined Aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2018;12(12):Cd011594. doi:10.1002/14651858.CD011594.pub2
   PubMed Web of Science ®Google Scholar
• Sliwka A, Jankowski M, Gross-Sondej I, Storman M, Nowobilski R, Bala MM. Once-daily long-acting beta2-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018;8(8):Cd012355. doi:10.1002/14651858.CD012355.pub2
   PubMedGoogle Scholar
• McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;2:Cd003793. doi:10.1002/14651858.CD003793.pub3
   PubMed Web of Science ®Google Scholar
• Zwerink M, Brusse-Keizer M, van der Valk PD, et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(3):Cd002990. doi:10.1002/14651858.CD002990.pub3
   PubMed Web of Science ®Google Scholar
• Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and medicare patients. Int J Chron Obstruct Pulmon Dis. 2012;7:1–9. doi:10.2147/COPD.S27032
   PubMed Web of Science ®Google Scholar
• Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, temporal stability and appropriateness of therapy of patients with COPD in the UK in relation to GOLD 2019. EClinicalMedicine. 2019;14:32–41. doi:10.1016/j.eclinm.2019.07.003
   PubMedGoogle Scholar
• Riley CM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321(8):786–797. doi:10.1001/jama.2019.0131
   PubMed Web of Science ®Google Scholar
• Hurst JR, Winders T, Worth H, et al. A patient charter for chronic obstructive pulmonary disease. Adv Ther. 2021;38(1):11–23. doi:10.1007/s12325-020-01577-7
   PubMed Web of Science ®Google Scholar
• Johnston KN, Young M, Grimmer-Somers KA, Antic R, Frith PA. Why are some evidence-based care recommendations in chronic obstructive pulmonary disease better implemented than others? Perspectives of medical practitioners. Int J Chron Obstruct Pulmon Dis. 2011;6:659–667. doi:10.2147/COPD.S26581
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Chronic obstructive pulmonary disease; 2018. Available from: http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf. Accessed August 17, 2020.
   Google Scholar
• British Thoracic Society. BTS chronic obstructive pulmonary disease (COPD) discharge care bundle. Available from: https://www.brit-thoracic.org.uk/quality-improvement/clinical-resources/copd-spirometry/. Accessed August 31, 2020.
   Google Scholar
• Davies F, Risør MB, Melbye H, et al. Primary and secondary care clinicians’ views on self-treatment of COPD exacerbations: a multinational qualitative study. Patient Educ Couns. 2014;96(2):256–263. doi:10.1016/j.pec.2014.05.011
   PubMed Web of Science ®Google Scholar
• Gavish R, Levy A, Dekel OK, Karp E, Maimon N. The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. Chest. 2015;148(2):375–381. doi:10.1378/chest.14-1453
   PubMed Web of Science ®Google Scholar
• Sharma G, Kuo YF, Freeman JL, Zhang DD, Goodwin JS. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010;170(18):1664–1670. doi:10.1001/archinternmed.2010.345
   PubMed Web of Science ®Google Scholar
• Gómez-Angelats E, Sánchez C. Care bundles after discharging patients with chronic obstructive pulmonary disease exacerbation from the emergency department. Med Sci. 2018;6(3). doi:10.3390/medsci6030063
   Google Scholar
• Morton K, Sanderson E, Dixon P, et al. Health Services and Delivery Research. Care bundles to reduce re-admissions for patients with chronic obstructive pulmonary disease: a mixed-methods study. Southampton (UK): NIHR Journals Library; 2019.
   Google Scholar
• Hurst J, Legg M, Shanahan L, et al.; National Asthma and Chronic Obstructive Pulmonary Disease Audit Programme (NACAP). COPD clinical audit 2018/19 (people with COPD exacerbations discharged from acute hospitals in England, Scotland and Wales between September 2018 and 2019). Clinical audit report London: Royal College of Physicians; 2020. Available from: https://www.rcplondon.ac.uk/projects/national-asthma-and-copd-audit-programme-nacap-secondary-care-workstream-copd. Accessed August 31, 2020.
   Google Scholar
• Hopkinson NS, Englebretsen C, Cooley N, et al. Designing and implementing a COPD discharge care bundle. Thorax. 2012;67(1):90–92. doi:10.1136/thoraxjnl-2011-200233
   PubMed Web of Science ®Google Scholar
• Khdour MR, Kidney JC, Smyth BM, McElnay JC. Clinical pharmacy-led disease and medicine management programme for patients with COPD. Br J Clin Pharmacol. 2009;68(4):588–598. doi:10.1111/j.1365-2125.2009.03493.x
   PubMed Web of Science ®Google Scholar
• Khan A, Dickens AP, Adab P, Jordan RE. Self-management behaviour and support among primary care COPD patients: cross-sectional analysis of data from the Birmingham Chronic Obstructive Pulmonary Disease Cohort. NPJ Prim Care Respir Med. 2017;27(1):46. doi:10.1038/s41533-017-0046-6
   PubMed Web of Science ®Google Scholar
• McDonald VM, Osadnik CR, Gibson PG. Treatable traits in acute exacerbations of chronic airway diseases. Chron Respir Dis. 2019;16:1479973119867954. doi:10.1177/1479973119867954
   Web of Science ®Google Scholar
• Mantero M, Rogliani P, Di Pasquale M, et al. Acute exacerbations of COPD: risk factors for failure and relapse. Int J Chron Obstruct Pulmon Dis. 2017;12:2687–2693. doi:10.2147/COPD.S145253
   PubMed Web of Science ®Google Scholar
• Boutou AK, Shrikrishna D, Tanner RJ, et al. Lung function indices for predicting mortality in COPD. Eur Respir J. 2013;42(3):616–625. doi:10.1183/09031936.00146012
   PubMed Web of Science ®Google Scholar
• Chan SMH, Selemidis S, Bozinovski S, Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019;198:160–188. doi:10.1016/j.pharmthera.2019.02.013
   PubMed Web of Science ®Google Scholar
• Barreiro E, Jaitovich A. Muscle atrophy in chronic obstructive pulmonary disease: molecular basis and potential therapeutic targets. J Thorac Dis. 2018;10(Suppl 12):S1415–s1424. doi:10.21037/jtd.2018.04.168
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Román-Rodríguez M, Singh D, Han MK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: focus on symptoms and exacerbations. Respir Med. 2020;166:105938. doi:10.1016/j.rmed.2020.105938
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/s2213-2600(18)30006-7
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Voorham J, Dorinsky P, et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020;75(9):744–753. doi:10.1136/thoraxjnl-2019-214457
   PubMed Web of Science ®Google Scholar
• Sundh J, Janson C, Lisspers K, Ställberg B, Montgomery S. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE) index is predictive of mortality in COPD. Prim Care Respir J. 2012;21(3):295–301. doi:10.4104/pcrj.2012.00054
   PubMedGoogle Scholar
• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196. doi:10.1016/s0140-6736(12)61729-2
   PubMed Web of Science ®Google Scholar